行情

INCY

INCY

因塞特医疗
NASDAQ

实时行情|Nasdaq Last Sale

86.14
+1.28
+1.51%
盘前: 86.14 0 0.00% 08:00 11/13 EST
开盘
84.88
昨收
84.86
最高
86.53
最低
84.32
成交量
96.33万
成交额
--
52周最高
89.30
52周最低
57.00
市值
185.54亿
市盈率(TTM)
46.21
分时
5日
1月
3月
1年
5年

分析师评级

20位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

INCY 新闻

  • Here's Why Kadmon Holdings Stock Jumped Today
  • MotleyFool.com.17小时前
  • The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
  • Zacks.1天前
  • CORRECTED-INSIGHT-US company directors compensated more than ever, but now risk backlash
  • Reuters.1天前
  • INSIGHT-US company directors compensated more than ever, but now risk backlash
  • Reuters.4天前

更多

所属板块

生物技术和医学研究
+0.28%
制药与医学研究
+0.27%

热门股票

名称
价格
涨跌幅

INCY 简况

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.
展开

Webull提供Incyte Corporation的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。